<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04244435</url>
  </required_header>
  <id_info>
    <org_study_id>TEA-CABG</org_study_id>
    <nct_id>NCT04244435</nct_id>
  </id_info>
  <brief_title>Neuroaxial Prophylaxis for CABG</brief_title>
  <official_title>Consequences of Using Thoracic Epidural Analgesia for Coronary Artery Bypass Grafting</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Volgograd State Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Volgograd State Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigators plan to study the effect of thoracic epidural analgesia on postoperative
      parameters (complication rate, duration of hospitalization, mortality, etc.) of coronary
      artery bypass grafting.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Investigators plan to conduct a comparative analysis of early postoperative complications of
      coronary artery bypass grafting with and without cardiopulmonary bypass in patients with
      independent risk factors for the development of postoperative complications (advanced age,
      diabetes mellitus, chronic kidney disease, obesity, chronic obstructive pulmonary disease)
      with various types of anesthesiology benefits (general anesthesia and thoracic epidural
      analgesia versus general anesthesia and opioids). Investigators predict a decrease in the
      risk of developing cardiac, respiratory, infectious and renal complications, a reduction in
      the duration of intensive care, inpatient treatment and mortality.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">February 1, 2020</start_date>
  <completion_date type="Anticipated">January 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>hospital mortality</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Hospitalization duration</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of treatment in the intensive care unit</measure>
    <time_frame>up to 1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complications</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Coronary Artery Occlusion</condition>
  <arm_group>
    <arm_group_label>Thoracic epidural analgesia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CABG and thoracic epidural analgesia will be used for perioperative analgesia postoperative period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Opioids</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CABG and opioids will be used for perioperative analgesia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CABG</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>coronary artery bypass grafting with and without cardiopulmonary bypass</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>CABG</intervention_name>
    <description>coronary artery bypass grafting with and without cardiopulmonary bypass</description>
    <arm_group_label>CABG</arm_group_label>
    <arm_group_label>Opioids</arm_group_label>
    <arm_group_label>Thoracic epidural analgesia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>thoracic epidural analgesia</intervention_name>
    <description>thoracic epidural analgesia at the level of 1-10 thoracic vertebrae (ropivacainum 0,2-0,5% 5-10 ml/h)</description>
    <arm_group_label>Thoracic epidural analgesia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>analgesia of opioids</intervention_name>
    <description>Opioids will be used for perioperative analgesia</description>
    <arm_group_label>Opioids</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  coronary artery bypass grafting

        Exclusion Criteria:

          -  Absolute contraindications for the use of thoracic epidural analgesia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital â„–1 of Volgograd State Medical University</name>
      <address>
        <city>Volgograd</city>
        <zip>400079</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>January 20, 2020</study_first_submitted>
  <study_first_submitted_qc>January 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 28, 2020</study_first_posted>
  <last_update_submitted>February 1, 2020</last_update_submitted>
  <last_update_submitted_qc>February 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Volgograd State Medical University</investigator_affiliation>
    <investigator_full_name>Mikhail I Turovets, MD</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>coronary artery bypass grafting</keyword>
  <keyword>prevention of complication</keyword>
  <keyword>neuroaxial prophylaxis</keyword>
  <keyword>thoracic epidural analgesia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Occlusion</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

